Fundraising Fox

Atavistik Bio

Founded 2021 · 40 employees on LinkedIn · 4 known investors

Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology. The company is advancing multiple drug programs toward regulatory approval and clinical applications for patients with significant unmet medical needs.

BiotechHealthtechMedical Devices

Founders & leadership

BE
Bryan E. StuartinChief Executive Officer
MDMarion Dorsch
Marion DorschinPresident and Chief Scientific Officer

Investors · 4

Lux Capital✓ verifiedNew York · $100K – $100M
RA Capital✓ verifiedBoston
The Column Group✓ verifiedSan Francisco · $30M
Nextech InvestZurich · $648K – $3.2M

Funding

SEC filings, press & company announcements

$120M disclosed across 1 of 3 rounds · 2023–2026

  • Undisclosed amountSeries B ExtensionMar 2026
    Source ↗
  • $120MSeries B FinancingDec 2025 · 2 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

New funding, new jobs: 4 biotechs hiring after series B raises - BioSpacebiospace.com · Jul 2026Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Millionglobenewswire.com · Mar 2026Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new fundsfiercebiotech.com · Dec 2025Atavistik Bio Raises $120 Million Series B | citybizcitybiz.co · Dec 2025Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)globenewswire.com · Dec 2025Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeuticsglobenewswire.com · Dec 2023

Frequently asked questions

What does Atavistik Bio do?
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology. The company is advancing multiple drug programs toward regulatory approval and clinical applications for patients with significant unmet medical needs.
Who are Atavistik Bio's investors?
Atavistik Bio's investors include Lux Capital, RA Capital, The Column Group, Nextech Invest.
How much funding has Atavistik Bio raised?
Atavistik Bio has disclosed $120M raised across 1 of its 3 known rounds.